PT - JOURNAL ARTICLE AU - Andrew Dunbar AU - Kelly L. Bolton AU - Sean M. Devlin AU - Francisco Sanchez-Vega AU - Jianjiong Gao AU - Jodi V. Mones AU - Jonathan Wills AU - Daniel Kelly AU - Mirko Farina AU - Keith Cordner AU - Young Park AU - Sirish Kishore AU - Krishna Juluru AU - Neil M. Iyengar AU - Ross L. Levine AU - Ahmet Zehir AU - Wungki Park AU - Alok A. Khorana AU - Gerald A. Soff AU - Simon Mantha TI - Genomic Profiling Identifies Somatic Mutations Predicting Thromboembolic Risk in Patients with Solid Tumors AID - 10.1101/2020.06.09.20124925 DP - 2020 Jan 01 TA - medRxiv PG - 2020.06.09.20124925 4099 - http://medrxiv.org/content/early/2020/06/12/2020.06.09.20124925.short 4100 - http://medrxiv.org/content/early/2020/06/12/2020.06.09.20124925.full AB - Cancer-associated venous thromboembolism (CAT) is a well-described complication of cancer and a leading cause of death in cancer patients. The purpose of this study was to assess potential associations of molecular signatures with CAT, including tumor-specific mutations and the presence of clonal hematopoiesis. We analyzed deep-coverage targeted DNA-sequencing data of >14,000 solid tumor samples using the MSK-IMPACT™ platform to identify somatic alterations associated with VTE. Endpoint was defined as the first instance of cancer-associated pulmonary embolism and/or proximal/distal lower extremity deep vein thrombosis. Cause-specific Cox proportional hazards regression was used, adjusting for pertinent clinical covariates. Of 11,695 evaluable individuals, 72% had metastatic disease at time of IMPACT. Tumor-specific mutations in KRAS (HR=1.34 [1.09-1.64]; adjusted p=0.08), STK11 (HR=2.12 [1.55-2.89]; adjusted p<0.001), KEAP1 (HR=1.84 [1.21-2.79]; adjusted p=0.07), CTNNB1 (HR=1.73 [1.15-2.60]; adjusted p=0.09), CDKN2B (HR= 1.45 [1.13-1.85], adjusted p=0.07) and MET (HR=1.83 [1.15-2.92]; adjusted p=0.09) were associated with a significantly increased risk of CAT independent of tumor type. Mutations in SETD2 were associated with a decreased risk of CAT (HR=0.35 [0.16-0.79], adjusted p=0.09). The presence of clonal hematopoiesis was not associated with an increased VTE rate. This is the first large-scale analysis to elucidate tumor-specific genomic events associated with CAT. Somatic tumor mutations of STK11, KRAS, CTNNB1, KEAP1, CDKN2B and MET were associated with an increased risk of VTE in solid tumor patients. Further analysis is needed to validate these findings and identify additional molecular signatures unique to individual tumor types.Key PointsTumor mutations in STK11, KRAS, CTNNB1, KEAP1, CDKN2B, MET and SETD2 modulate the risk of cancer-associated thrombosis.The presence of clonal hematopoiesis does not affect the risk of cancer-associated thrombosis.Competing Interest StatementS.K. serves as a consultant to Inari Medical. R.L.L. is on the supervisory board of Qiagen; is a scientific advisor to Loxo, Imago, C4 Therapeutics, and Isoplexis, each of which includes equity interest; receives research support from and consulted for Celgene and Roche; received research support from Prelude Therapeutics; has consulted for Lilly, Janssen, Incyte, Novartis, and Gilead; and has received honoraria from Lilly and Amgen for invited lectures. W.P. receives funding from Merck, Astellas, and Gossamerbio, and is a consultant to Ipsen. A.K. received fees from Janssen, Bayer, Sanofi, Parexel, Halozyme, Pfizer, Seattle Genetics, Pharmacyclics, Pharmacyte, AngioDynamics, Leo Pharma, TriSalus and Medscape, along with grant support from Merck, Array, Bristol Myers Squibb and Leap. S.M. is principal owner of Daboia Consulting LLC. J.V.M. received fees from Sobi/Dova Pharmaceuticals. N.M.I. received consulting fees from Novartis and Seattle Genetics, along with grant support from Novartis.Funding StatementMemorial Sloan Kettering research support: NIH/NCI Cancer Center Support Grant P30 CA008748. Dr. Dunbar receives support from the American Association of Cancer Research (17-40-11-DUNB) Dr. Khorana acknowledges additional research support from the Sondra and Stephen Hardis Chair in Oncology Research and the National Heart, Lung and Blood Institute (U01HL143402). Dr Park receives funding from the NIH (K12 CA184746 Paul Calabresi Award), the Parker Institute for Cancer Immunotherapy and SITC - Sparkathon TimIOs. Dr Iyengar receives research support from the NCI/NIH (R01CA235711), the Breast Cancer Research Foundation and the American Cancer Society. J.G. was supported by the Marie-Josee and Henry R. Kravis Center for Molecular Oncology. Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Memorial Sloan Kettering IRB approved this retrospective study and waived the requirement for written consent.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesGenomic data is available publicly on cBioPortal. Other data available on request from manthas@mskcc.org. http://cbioportal.org